Ignite Creation Date:
2024-10-26 @ 3:40 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06592768
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-06
Brief Title:
A Double-blind Placebo-controlled Parallel-group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants with Allergic Asthma
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Double-Blind Placebo-Controlled Parallel-Group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants with Allergic Asthma
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Study JSP-CP-012 is designed as a proof of concept parallel-group single dose double blind placebo-controlled study using an allergen challenge model A single dose proof of concept approach at a dose level shown to be biologically active should inform the impact of briquilimab on allergic asthma as compared to placebo while minimizing exposure to participants in a new indication
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None